Skip to main content

Full text of "USPTO Patents Application 10551504"

See other formats 


Sheet 1 of 2 



Substitute Form PTO-1449 U.S. Department of Commerce 
(Modified) Patent and Trademark Office 

Information Disclosure Statement 
by Applicant 

(Use several sheets if necessary) 

(37 CFR §1 .98(b)) 


Attorney Docket No. 

14875-0153US1 


Application No. 

10/551,504 


Applicant 

Hiroyiiki Tsunoda et al. 


Filing Date 

September 29, 2005 


Group Art Unit 

1647 



U.S. Patent Documents 


Examiner 
Initial 


Desig. 
ID 


Document 
Number 


Publication 
Date 


Patentee 


Class 


Subclass 


Filing Date 
If Appropriate 




1 


4,946,778 


08/07/1990 


Ladner et al. 










2 


5,789,554 


08/04/1998 


Leung et al. 










3 


7,456,260 


1 1/25/2008 


Rybak et al. 










4 


2008/0248037 


10/09/2008 


Li et al. 










5 


2009/0214535 


08/27/2009 


Igawa et al 










Foreign Patent Documents or Pub 


ished Foreign Patent Applications 


Examiner 


Desig. 


Document 


Publication 


Country or 






Translation 


Initial 


ID 


Number 


Date 


Patent Office 


Class 


Subclass 


Yes 


No 




6 


WO 99/12973 


03/18/1999 


WIPO 






English 
abstract 






7 


WO 2004/003019 


01/08/2004 


WIPO 











( 


Dther Documents (include Author, Title, Date, and Place of Publication) 


Examiner 
Initial 


Desig. 
ID 


Document 




8 


ARNDT et al, "Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain 
Fv Yra^enX," Biochemistry, 37:12918-12926 (1998) 




9 


DUFNER et al , "Harnessing phage and ribosome display for antibody optimization," Trends 

Biotechnol, 24(ll):523-529 (2006) 




10 


ICHIKAWA et al, "Tumoricidal activity of a novel anti-himian DR5 monoclonal antibody without 
hepatocyte cytotoxicity," A/a/. Med., 7:954-960 (2001) 




11 


MATEO et al., "CD47 ligation induces caspase-independent cell death in chronic lymphocytic 
leukemia," A/fl?. Med., 5(11): 1277-1284 (1999) 




12 


PAUL, Fundamental Immunology, 3rd Edition, Raven Press, NY, Chapter 8, pp. 292-295 (1993) 




13 


WAKELEE et al., "Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 
weeks in patients with advanced solid tumors," Ann. Oncol. On-line publication (7/24/2009) 




14 


WARD et al, "Binding activities of a repertoire of single immimoglobulin variable domains 
secreted from Escherichia coh," Nature, 341:544-546 (1989) 




15 


WHITLOW et al, "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation 
of abispecific Yn," Protein Eng., 7(8): 1017-1026 (1994) 




16 


YAGITA et al., "TRAIL and its receptors as targets for cancer therapy," Cancer Sci., 95:777-783 
(2004) 




17 


FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 16, 2009 in U.S. App. 
Ser. No. 10/550,934, filed September 10, 2009, 75 pages 




18 


U.S. EXAMESIER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. 
No. 10/582,304, mailed September 15, 2009, 22 pages 



Examiner Signature 


Date Considered 


EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with 


next communication to applicant. 




Substitute Disclosure Form (PTO-1449) 



Sheet 2 of 2 



Substitute Form PTO-1449 U.S. Department of Commerce 
(IVlodified) Patent and Trademark Office 

Information Disclosure Statement 
by Applicant 

(Use several sheets if necessary) 

(37 CFR §1 .98(b)) 


Attorney Docket No. 

14875-0153US1 


Application No. 

10/551,504 


Applicant 

Hiroyiiki Tsunoda et al. 


Filing Date 

September 29, 2005 


Group Art Unit 

1647 



( 


Dther Documents (include Author, Title, Date, and Place of Publication) 


Examiner 
Initial 


Desig. 
ID 


Document 




19 


KLARQUIST SPARKMAN, LLP Response to Restriction Requirement dated May 26, 2009 in U.S. 

App. Ser. No. 10/582,654, filed June 23, 2009, 2 pages 




20 


U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. 
No. 10/582,654, mailed September 1, 2009, 36 pages 




21 


U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. 

No. 10/399,518, mailed September 11, 2009, 24 pages 




22 


U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. 
No. 10/257,864, mailed February 1, 2006, 14 pages 



Examiner Signature 


Date Considered 


EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with 


next communication to applicant. 




Substitute Disclosure Form (PTO-1449)